BioMarin – Update for Achondroplasia Associations

As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin clinical studies. The safety and well-being of study participants, healthcare
providers, and our communities is paramount as the ongoing COVID-19 pandemic impacts the health and livelihoods of many worldwide.

BioMarin Pharmaceutical, Inc., April 2020

Click here for full report.

The Chandler Project (TCP) provides those affected with achondroplasia, and other forms of skeletal dysplasia (dwarfism), with the latest in pharmaceutical research and surgical advancements. Since 2019, TCP has hosted the only conference in North America that brings together individuals and their families, physicians, researchers, biotech industries and more together at the annual Achondroplasia Research Conference.